Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab

Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab

Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, targeting the sepsis- and inflammation-based vascular and capillar...

Full description

Bibliographic Details
Main Authors: Mahir Karakas, Dominik Jarczak, Martin Becker, Kevin Roedl, Marylyn M. Addo, Frauke Hein, Andreas Bergmann, Jens Zimmermann, Tim-Philipp Simon, Gernot Marx, Marc Lütgehetmann, Axel Nierhaus, Stefan Kluge
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Biomolecules
Subjects:
COVID-19
Adrecizumab
HAM 8101
adrenomedullin
endothelial function
Online Access:https://www.mdpi.com/2218-273X/10/8/1171

Internet

https://www.mdpi.com/2218-273X/10/8/1171

Similar Items